To investigate whether hnRNPL mediates the role of FBXO16 in ovarian cancer, we further used the CRISPR/Cas9 system to knockdown hnRNPL and FBXO16 individually or simultaneously (Fig. 6A). This evidence concerns the gene FBXO16 and ovarian carcinoma.